In conclusion, RLN2 secreted by engineered CAR-T cells demonstrated specific MMP-inducing capabilities, promoted collagen degradation in vivo, and improved tumor suppression in xenograft models with abundant stroma. The gene discussed is RLN2; the disease is neoplasm.